Oncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressors

Genes and Development

Volumn 27, Issue 20, 2013, Pages 2221-2226

  Wajapeyee, Narendra ^a   Malonia, Sunil K ^b   Palakurthy, Rajendra K ^b   Green, Michael R ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

DNMT1; Epigenetic silencing; Epistasis analysis; RAS; RNA interference; ZFP354B

Indexed keywords

DNA BINDING PROTEIN; DNA METHYLTRANSFERASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; ZINC FINGER PROTEIN;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; DNA METHYLATION; DNA REPLICATION; EPISTASIS; GENE SILENCING; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

DNMT1; EPIGENETIC SILENCING; EPISTASIS ANALYSIS; RAS; RNA INTERFERENCE; ZFP354B;

ANIMALS; ANTIGENS, CD95; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; MICE; MODELS, BIOLOGICAL; NIH 3T3 CELLS; PROTEIN BINDING; RAS PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84885908156     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.227413.113     Document Type: Article

References (27)

1. Berger AH, Knudson AG, Pandolfi PP. 2011. A continuum model for tumour suppression. Nature 476: 163-169.
2. Chang CJ, Hung MC. 2012. The role of EZH2 in tumour progression. Br J Cancer 106: 243-247.
3. Croonquist PA, Van Ness B. 2005. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24: 6269-6280.
4. Datta S, Hoenerhoff MJ, Bommi P, Sainger R, Guo WJ, Dimri M, Band H, Band V, Green JE, Dimri GP. 2007. Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways. Cancer Res 67: 10286-10295.
5. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. 2012. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 16: S17-S27.
6. Downward J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22.
7. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632.
8. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR. 2007. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449: 1073-1077.
9. Gribenko AV, Hopper JE, Makhatadze GI. 2001. Molecular characterization and tissue distribution of a novel member of the S100 family of EF-hand proteins. Biochemistry 40: 15538-15548.
10. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ, Counter CM. 2002. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16: 2045-2057.
11. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144: 646-674.
12. Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U, Stahel R. 2003. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10: 356-364.
13. Jin B, Robertson KD. 2013. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol 754: 3-29.
14. Kulis M, Esteller M. 2010. DNA methylation and cancer. Adv Genet 70: 27-56.
15. Maecker HL, Yun Z, Maecker HT, Giaccia AJ. 2002. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2: 139-148.
16. Margueron R, Reinberg D. 2011. The Polycomb complex PRC2 and its mark in life. Nature 469: 343-349.
17. Morrison DK. 2012. MAP kinase pathways. Cold Spring Harb Perspect Biol 4: a011254.
18. Peli J, Schroter M, Rudaz C, Hahne M, Meyer C, Reichmann E, Tschopp J. 1999. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J 18: 1824-1831.
19. Ptashne M. 2007. On the use of the word 'epigenetic'. Curr Biol 17: R233-R236.
20. Raimondi C, Falasca M. 2011. Targeting PDK1 in cancer. Curr Med Chem 18: 2763-2769.
21. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J. 1997. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89: 457-467.
22. Santra MK, Wajapeyee N, Green MR. 2009. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 459: 722-725.
23. Urquhart JL, Meech SJ, Marr DG, Shellman YG, Duke RC, Norris DA. 2002. Regulation of Fas-mediated apoptosis by N-ras in melanoma. J Invest Dermatol 119: 556-561.
24. Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248.
25. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. 2013. Cancer genome landscapes. Science 339: 1546-1558.
26. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M, Wigler MH. 1995. Multiple Ras functions can contribute to mammalian cell transformation. Cell 80: 533-541.
27. Wu SC, Zhang Y. 2010. Active DNA demethylation: Many roads lead to Rome. Nat Rev Mol Cell Biol 11: 607-620.